News & insights

*Breaking News – Board upholds decision to revoke CRISPR patent*

News

*Breaking News – Board upholds decision to revoke CRISPR patent*

The Board of Appeal has today confirmed that the Opposition Division (OD) was correct in deciding that priority claims of CRISPR patent EP2771468 are invalid and therefore the claimed subject matter lacks novelty over papers published in the priority year. The patentees’ appeal was dismissed and the OD’s decision to revoke the patent has become final.

Good news - an update on ORKAMBI availability for cystic fibrosis patients in the UK

News

Good news - an update on ORKAMBI availability for cystic fibrosis patients in the UK

News last month reports that an agreement has now be made, after years of dispute, for patients in England to have access to ORKAMBI though NHS England. The drug was authorised over four years ago, but the price asked by Vertex was “unaffordable” according to the NHS.

SPC News – Advocate General (AG) Opinion in CJEU referrals C-114/18 (Sandoz) and C-650/17 (Royalty Pharma)

News

SPC News – Advocate General (AG) Opinion in CJEU referrals C-114/18 (Sandoz) and C-650/17 (Royalty Pharma)

As expected, the AG published his opinion in the above CJEU referrals on the 11th September 2019. The issue at hand is the interpretation of Article 3(a) of the SPC Regulation (EC 469/2009) which states that an SPC shall be granted for a ‘product protected by a basic patent in force’.

EPO Decision G 1/16 - A victory for common-sense?

Thoughts

EPO Decision G 1/16 - A victory for common-sense?

At the highest level of the EPO, the Enlarged Board of Appeal continues to deliver EPO binding decisions on technical and legal issues. For those of you interested in the ever relevant matter of disclaimers at the EPO, here’s the latest news, in the form of Decision G 1/16.

Patent Box improves large companies’ finances, but is UK innovation getting the same reward?

News

Patent Box improves large companies’ finances, but is UK innovation getting the same reward?

The most recent official statistics on Patent Box show an increase in the amount of relief claimed, which should be good news for business, innovation and the UK economy.

*Breaking News – Board upholds decision to revoke CRISPR patent*

News

*Breaking News – Board upholds decision to revoke CRISPR patent*

The Board of Appeal has today confirmed that the Opposition Division (OD) was correct in deciding that priority claims of CRISPR patent EP2771468 are invalid and therefore the claimed subject matter lacks novelty over papers published in the priority year. The patentees’ appeal was dismissed and the OD’s decision to revoke the patent has become final.

Good news - an update on ORKAMBI availability for cystic fibrosis patients in the UK

News

Good news - an update on ORKAMBI availability for cystic fibrosis patients in the UK

News last month reports that an agreement has now be made, after years of dispute, for patients in England to have access to ORKAMBI though NHS England. The drug was authorised over four years ago, but the price asked by Vertex was “unaffordable” according to the NHS.

SPC News – Advocate General (AG) Opinion in CJEU referrals C-114/18 (Sandoz) and C-650/17 (Royalty Pharma)

News

SPC News – Advocate General (AG) Opinion in CJEU referrals C-114/18 (Sandoz) and C-650/17 (Royalty Pharma)

As expected, the AG published his opinion in the above CJEU referrals on the 11th September 2019. The issue at hand is the interpretation of Article 3(a) of the SPC Regulation (EC 469/2009) which states that an SPC shall be granted for a ‘product protected by a basic patent in force’.

Patent Box improves large companies’ finances, but is UK innovation getting the same reward?

News

Patent Box improves large companies’ finances, but is UK innovation getting the same reward?

The most recent official statistics on Patent Box show an increase in the amount of relief claimed, which should be good news for business, innovation and the UK economy.

Let us keep you up to date. If you’d like to receive communications from us, ranging from breaking news to technical updates, thought leadership to event invitations, please let us know.

Connect with us

Cookies improve the way our website works. By using this website you are agreeing to our use of cookies. For more information see our cookie policy I accept